[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100604027":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":54,"collaborators":26,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":26,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":26,"studyType":70,"phases":71,"briefSummary":60,"conditions":73,"keywords":26,"overallStatus":40,"whyStopped":26,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"A(RT)","EXPERIMENTAL","30 Subjects, Cross-over, Single dose DWC202501 on period 1, Single dose of DWJ1511 on period 2",[13,14],"Drug: DWJ1511","Drug: DWC202501",{"label":16,"type":17,"description":18,"interventionNames":19},"B(TR)","ACTIVE_COMPARATOR","30 Subjects, Cross-over, Single dose DWJ1511 on period 1, Single dose of DWC202501 on period 2",[13,14],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","DWJ1511","Test drug: DWJ1511",[9,16],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"DWC202501","Comparator: DWC202501",[9,16],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Kang","CONTACT","82) 070-4665-9490","juspa@newyjh.com",[38],{"facility":39,"status":40,"city":41,"state":26,"zip":42,"country":43,"countryCode":26,"cosmosGeoPoint":44,"geoPoint":49,"contacts":50},"H Plus Yangji Hospital","RECRUITING","Seoul","08779","South Korea",{"type":45,"coordinates":46},"Point",[47,48],126.9784,37.566,{"lat":48,"lon":47},[51],{"name":33,"role":34,"phone":52,"phoneExt":26,"email":53},"82) 070-4665-9476","juspa@newyji.com",{"type":55,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100604027","phase-1-pk-and-safety-comparison-of-dwj1511-and-dwc202501-in-healthy-volunteers-100604027",false,"NCT07144176","PK and Safety Comparison of DWJ1511 and DWC202501 in Healthy Volunteers","An Open-label, Randomized, Fasting, Single-dose, Two-treatment, Two-period, Crossover, Phase 1 Clinical Trial to Compare and Evaluate the Pharmacokinetics and Safety of \"DWJ1511\" and \"DWC202501\" in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Male or female participants aged ≥19 years and \\\u003C65 years at the time of screening\n* Body mass index (BMI) between 18 and 30 kg\u002Fm² (BMI = weight \\[kg\\] \u002F height \\[m\\]²)\n\nExclusion Criteria:\n\n* Subjects who have participated in a bioequivalence study or any other clinical trial and have received an investigational product within 6 months prior to the first administration.\n* Subjects who have donated whole blood within 8 weeks prior to the first administration, donated blood components within 2 weeks prior to the first administration, or received a blood transfusion within 4 weeks prior to the first administration.\n* Subjects with a history of gastrointestinal surgery that may affect drug absorption (appendectomy and hernia repair are not exclusionary).",true,"ALL","19 Years","64 Years",{"count":68,"type":69},60,"ESTIMATED","INTERVENTIONAL",[72],"PHASE1",[74],"Healthy Subjects","2025-08-27",{"date":77,"type":78},"2025-08-28","ACTUAL",{"date":80,"type":69},"2025-09",{"date":80,"type":69},{"name":5,"class":6},1]